Results 281 to 290 of about 65,249 (309)
Some of the next articles are maybe not open access.
Use of compassionate-case ATMP in preclinical data for clinical trial applications
The Lancet, 2012Mark W, Lowdell +2 more
openaire +2 more sources
Journal of experimental & clinical cancer research : CR, 2003
Imatinib mesylate (IM), is a selective and competitive inhibitor of tyrosine kinases, including BCR-ABL, ABL, KIT, and the platelet-derived growth factor receptors (PDGF-R). It binds to the ATP-binding site of the target kinase and prevents the transfer of phosphate from ATP to the tyrosine residues of various substrates.
Fiorentini G +7 more
openaire +2 more sources
Imatinib mesylate (IM), is a selective and competitive inhibitor of tyrosine kinases, including BCR-ABL, ABL, KIT, and the platelet-derived growth factor receptors (PDGF-R). It binds to the ATP-binding site of the target kinase and prevents the transfer of phosphate from ATP to the tyrosine residues of various substrates.
Fiorentini G +7 more
openaire +2 more sources
Hemoglobin-Based Oxygen Carriers: Compassionate Use and Compassionate Clinical Trials
Anesthesia & Analgesia, 2010openaire +2 more sources
An overview of precision oncology basket and umbrella trials for clinicians
Ca-A Cancer Journal for Clinicians, 2020Jay Park +2 more
exaly
Compassionate use trials and equitable access to variant-specific treatment for cystic fibrosis
The Lancet Respiratory MedicineKatherine, Odem-Davis +1 more
openaire +2 more sources
<b>Compassionate Use of Candidate Drugs in Pre-Clinical Trial Phase for Ebola Hemorrhagic Fever </b>
Rinsho yakuri/Japanese Journal of Clinical Pharmacology and Therapeutics, 2014Ryuzo HANADA, Hiroshi WATANABE
openaire +1 more source
Compassionate Use of Remdesivir for Patients with Severe Covid-19
New England Journal of Medicine, 2020Norio Ohmagari +2 more
exaly